BURLINGTON, N.C. and Alpharetta, Ga. — April 9, 2020 — LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Ciox Health, the leader in health information management for more than 30 years, today announced an agreement to collaborate on a comprehensive U.S.-based COVID-19 patient data registry. This registry will house curated, HIPAA-compliant de-identified data sets to expedite clinical research and analyses related to COVID-19. This patient data registry is expected to enable researchers to better understand and characterize COVID-19 diagnoses and treatments and generate insights that will aid ongoing and future pandemic preparedness and prevention efforts.
LabCorp and Ciox Health’s Real World Data division will work closely to expedite this first-of-its-kind patient data registry. LabCorp has performed approximately 500,000 tests since first making its COVID-19 test available March 5. The registry will leverage LabCorp’s deep scientific and research expertise and the unique, rapidly expanding de-identified datasets from its COVID-19 testing platform. To yield a more complete view of clinical paths and outcomes, this data set will be supplemented with additional longitudinal medical record data, compiled using the Ciox Health DataFit Platform™. The data sets will be compliantly and safely aggregated to rapidly construct research-grade clinical cohorts for a wide range of epidemiological, clinical and observational uses.
“Healthcare practitioners and researchers need dynamic and real-time insights about COVID-19 to address this health care crisis and develop better treatment options for patients,” said Lance Berberian, chief information and technology officer, LabCorp. “Combining life sciences and data sciences, including artificial intelligence and natural language processing, is the next frontier in the battle against the virus. We hope that this groundbreaking registry inspires more research and quickly results in improved outcomes for patients.”
Initially, LabCorp will analyze clinical de-identified data sets from its rapidly expanding diagnostic patient data sets. Once developed, there will be an opportunity to expand the capability to foster a data coalition that includes leading healthcare providers and other partners, such as state and federal public health organizations.
“Ciox can securely, safely and efficiently access and curate invaluable clinical data across the U.S. healthcare ecosystem for the fight against coronavirus in a way that is consistent with the highest standards of existing privacy rules and that does not distract front-line healthcare workers from caring for patients,” said Pete McCabe, CEO of Ciox Health. “A comprehensive data set will yield valuable insights and we are ready to support researchers and public health organizations to advance our collective understanding of this pandemic. We see this as only the beginning and are hopeful that, together, we and LabCorp will galvanize a public/private data sharing partnership to deepen our understanding of COVID-19 and other infectious diseases so we can plan for and manage these pandemics more effectively now and in the future.”
This data set will scale over the coming weeks and months to aggregate millions of data points relevant to the continued study of this mission-critical area of medicine and public health. These cohorts are expected to yield insights into possible host and environmental factors that drive susceptibility to, or protection from, the SARS-CoV-2 viral infection, along with risk factors associated with the severity of disease at presentation and associated outcomes based on interventions. A multitude of other questions about the disease course of COVID-19 in different people and how its trajectory may be altered may also be answered using this data set.
“The registry will enable researchers and clinicians to gain rapid insights from real world data, with the ultimate goal of improving the treatment and prevention of COVID-19. This important work speaks directly to LabCorp’s mission to improve health and improve lives,” said Oren Cohen, M.D., chief medical officer of LabCorp’s Covance Drug Development business and Fellow of the Infectious Diseases Society of America. “Agility is critical in our current situation. By design, this patient data registry will serve as a platform for meaningful and dynamic inquiry that can strengthen our defenses against the pandemic while it’s happening.”
Cohen serves as co-investigator of the patient data registry. Marcia Eisenberg, Ph.D., chief scientific officer at LabCorp Diagnostics, serves as the registry’s lead investigator. A scientific advisory committee is being formed, including experts in relevant scientific and medical disciplines, to guide the usage of the registry and support ongoing partnerships for research.
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019
Ciox Health, a leading health technology company, is improving patient health by transforming clinical data into actionable insights. Combined with an unmatched network offering ubiquitous and secure access to healthcare data, Ciox Health’s expertise, relationships, technology and scale make a difference for healthcare stakeholders and empower greater health for patients. Through its technology platform, which includes solutions for data acquisition, release of information, clinical coding, data abstraction, and analytics, Ciox Health helps clients securely and consistently solve the last mile challenges in clinical interoperability. Learn more about Ciox Health’s technology and solutions by visiting www.cioxhealth.com or Twitter and LinkedIn.
Utilizing its DataFit Platform™, the Ciox Real World Data division (Ciox RWD) assists providers with the ability to securely and consistently curate disparate data sets to enable researchers to access valuable clinical information that may otherwise be hidden in or across different parts of workflow systems that house medical records. The Ciox DataFit Platform™ utilizes clinical rules-based medical concept translation with unstructured data sets to build highly structured clinical data that can be used by researchers. Learn more at www.cioxrwd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to our responses to and the expected future impacts of the COVID-19 pandemic, strategic partnerships and scientific collaborations, the anticipated benefits of such partnerships and collaborations, and the expected impact that the various partnerships and collaborations may have on the Company’s financial results. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, and the Company’s ability to establish and maintain strategic partnerships and other scientific collaborations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.
Premier, Inc.’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials
Verisense Health Adopts Datavant’s Data Connectivity Platform to Expand its Digital Health Panel’s RWD Sources
Datavant Joins NSF and Partners in Launch of the National AI Research Resource (NAIRR) Pilot Providing Privacy-Preservation Technologies to Safeguard AI-Enabled Data
Explore how Datavant can be your health data logistics partner.Contact us